Cullinan Therapeutics, Inc.CGEM

$15.03+0.59 (+4.09%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$890M

Small-cap

-24%

2021 — today

10-Year Price

-46%

2021 — today

52-Week Range

$5.75$16.44

Current $15.03· 87%

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Valuation in context

P/E ratio

-4.0

N/A

Not meaningful — company is unprofitable

P/B ratio

2.4

Historically pricey

Historically pricey — last 10 years

FCF Yield

-20.1%

Around average

Around the 10-year average

Free · No credit card needed

Get alerted when CGEM is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.